SrasV1, PascalFrancis, Curation, bibRecord, 000484

Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

Identifieur interne : 000484 ( PascalFrancis/Curation ); précédent : 000483; suivant : 000485

Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Frank Vandermeer [Pays-Bas] ; Miguel Stevens [Belgique] ; Erik De Clercq [Belgique] ; Herman Egberink [Pays-Bas] ; Marc Van Ranst [Belgique]

Source :

Journal of antimicrobial chemotherapy : (Print) [ 0305-7453 ] ; 2006.

RBID : Pascal:06-0221426

Descripteurs français

Pascal (Inist)
- Pyridine dérivé, Homme, Syndrome respiratoire aigu sévère, Péritonite infectieuse féline, Coronavirus, In vitro, Culture cellulaire.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Cell culture, Coronavirus, Feline infectious peritonitis, Human, In vitro, Pyridine derivatives, Severe acute respiratory syndrome.

Abstract

Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50-100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.

A01	`01`	`1`		`@0 0305-7453`
A02	`01`			`@0 JACHDX`
A03		`1`		`@0 J. antimicrob. chemother. : (Print)`
A05				`@2 57`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture`
A11	`01`	`1`		`@1 BALZARINI (Jan)`
A11	`02`	`1`		`@1 KEYAERTS (Els)`
A11	`03`	`1`		`@1 VIJGEN (Leen)`
A11	`04`	`1`		`@1 VANDERMEER (Frank)`
A11	`05`	`1`		`@1 STEVENS (Miguel)`
A11	`06`	`1`		`@1 DE CLERCQ (Erik)`
A11	`07`	`1`		`@1 EGBERINK (Herman)`
A11	`08`	`1`		`@1 VAN RANST (Marc)`
A14	`01`			`@1 Rega Institute for Medical Research, K. U. Leuven @2 Leuven @3 BEL @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 Institute of Virology, Faculty of Veterinary Medicine, Utrecht University @2 Utrecht @3 NLD @Z 4 aut. @Z 7 aut.`
A20				`@1 472-481`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17084 @5 354000132490250110`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 06-0221426`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of antimicrobial chemotherapy : (Print)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50-100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.
C02	`01`	`X`		`@0 002B02S`
C03	`01`	`X`	`FRE`	`@0 Pyridine dérivé @5 01`
C03	`01`	`X`	`ENG`	`@0 Pyridine derivatives @5 01`
C03	`01`	`X`	`SPA`	`@0 Piridina derivado @5 01`
C03	`02`	`X`	`FRE`	`@0 Homme @5 02`
C03	`02`	`X`	`ENG`	`@0 Human @5 02`
C03	`02`	`X`	`SPA`	`@0 Hombre @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 04`
C03	`03`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 04`
C03	`03`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 04`
C03	`04`	`X`	`FRE`	`@0 Péritonite infectieuse féline @5 05`
C03	`04`	`X`	`ENG`	`@0 Feline infectious peritonitis @5 05`
C03	`04`	`X`	`SPA`	`@0 Peritonitis infecciosa felina @5 05`
C03	`05`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 06`
C03	`05`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 06`
C03	`05`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 06`
C03	`06`	`X`	`FRE`	`@0 In vitro @5 07`
C03	`06`	`X`	`ENG`	`@0 In vitro @5 07`
C03	`06`	`X`	`SPA`	`@0 In vitro @5 07`
C03	`07`	`X`	`FRE`	`@0 Culture cellulaire @5 08`
C03	`07`	`X`	`ENG`	`@0 Cell culture @5 08`
C03	`07`	`X`	`SPA`	`@0 Cultivo celular @5 08`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 142`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000506

Links to Exploration step

Pascal:06-0221426

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0221426</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0221426 INIST</idno>
<idno type="RBID">Pascal:06-0221426</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000506</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000484</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of antimicrobial chemotherapy : (Print)</title>
<title level="j" type="abbreviated">J. antimicrob. chemother. : (Print)</title>
<idno type="ISSN">0305-7453</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of antimicrobial chemotherapy : (Print)</title>
<title level="j" type="abbreviated">J. antimicrob. chemother. : (Print)</title>
<idno type="ISSN">0305-7453</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell culture</term>
<term>Coronavirus</term>
<term>Feline infectious peritonitis</term>
<term>Human</term>
<term>In vitro</term>
<term>Pyridine derivatives</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pyridine dérivé</term>
<term>Homme</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Péritonite infectieuse féline</term>
<term>Coronavirus</term>
<term>In vitro</term>
<term>Culture cellulaire</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50-100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0305-7453</s0>
</fA01>
<fA02 i1="01"><s0>JACHDX</s0>
</fA02>
<fA03 i2="1"><s0>J. antimicrob. chemother. : (Print)</s0>
</fA03>
<fA05><s2>57</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BALZARINI (Jan)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KEYAERTS (Els)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VIJGEN (Leen)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VANDERMEER (Frank)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STEVENS (Miguel)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DE CLERCQ (Erik)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>EGBERINK (Herman)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>VAN RANST (Marc)</s1>
</fA11>
<fA14 i1="01"><s1>Rega Institute for Medical Research, K. U. Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>472-481</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17084</s2>
<s5>354000132490250110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0221426</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of antimicrobial chemotherapy : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objectives: Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture. Methods: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine N-oxide derivatives was monitored by spectrophotometric analysis. Results and conclusions: A wide variety of pyridine N-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine N-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50-100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine N-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pyridine dérivé</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Pyridine derivatives</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Piridina derivado</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Péritonite infectieuse féline</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Feline infectious peritonitis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Peritonitis infecciosa felina</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>In vitro</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>In vitro</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>In vitro</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Culture cellulaire</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cell culture</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cultivo celular</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>142</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0221426
   |texte=   Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

Pyridine n-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri